GENELUX Corp
No enriched coverage for $GNLX in the last 7 days.
No SEC Form 4 filings for $GNLX in the last 30 days.
Yu Yong, SVP of Clinical Development at Genelux Corp (NASDAQ:GNLX), sold 906 shares for $2.42 each, totaling $2192, to cover taxes on restricted stock units. This transaction occurred amidst a 39% year-to-date decline in GNLX shares, which are near their 52-week low. The company, with a market cap of $117.59 million, has a "WEAK" financial health score and is burning cash quickly.
Genelux (GNLX) Head of Regulatory, Ralph Smalling, sold a total of 585 shares of common stock on March 24 and 25, 2026, at prices between $2.42 and $2.51 per share. These transactions were made to cover estimated taxes related to vesting restricted stock units. Following these sales, Smalling's direct holdings in GENELUX common stock amount to 68,073 shares.
Genelux Corporation announced the pricing of an underwritten public offering of common stock, aiming to raise $20 million. The company plans to sell 6,666,667 shares at $3.00 each, with the offering expected to close on January 9, 2026. The proceeds are intended for general corporate purposes, including research and development.
